{"brief_title": "Double-Blind, Randomized, Dose Ranging Study of Alferon LDO (Low Dose Oral Interferon Alfa-n3 (Human Leukocyte Derived)) in HIV+ Subjects", "brief_summary": "To conduct a double-blind, randomized, dose ranging study of an orally administered low dose interferon alfa-n3 (IFN-An3) immunomodulator in the treatment of symptomatic HIV+ subjects.", "condition": ["HIV Infections"], "intervention_type": ["Drug"], "intervention_name": ["Interferon alfa-n3"], "criteria": "Inclusion Criteria Concurrent Medication: Allowed: - Zidovudine (AZT). - Didanosine (ddI) Patients must have: - Seropositivity to HIV-1 by ELISA and Western blot. - At least 1 of the HIV-related clinical symptoms or opportunistic infections listed in protocol. - Written informed consent. - If already on zidovudine (AZT) or didanosine (ddI), must have been on this therapy for at least 75 of the 90 days prior to study entry. Prior Medication: Allowed: - Zidovudine (AZT). - Didanosine (ddI) Exclusion Criteria Co-existing Condition: Patients with the following conditions or symptoms are excluded: - Major active opportunistic infection requiring active care within 2 weeks of study entry. - Evidence of chronic hepatitis with severe liver dysfunction: - albumin < 2 g/dl and SGOT or SGPT > 5 x upper limit of normal prothrombin time > 1.5 x upper limit of normal). - Other active gastrointestinal, renal, respiratory, endocrine, hematologic, cardiovascular, neurologic, or psychiatric disorder. - Transfusion dependency defined as requiring > 1 unit of packed red blood cells (RBC) per month within 3 months prior to study entry. Concurrent Medication: Excluded: - Experimental medications other than didanosine (ddI). - Chronic prophylactic use of any topical or systemic fungal medication such as ketoconazole, fluconazole, or clotrimazole. - Chronic prophylactic use of any topical or systemic anti-viral medication such as acyclovir or ganciclovir except zidovudine (AZT) or didanosine (ddI). Patients with the following are excluded: - Asymptomatic at study entry. - Presence of antibodies to interferon due to prior therapy. - Hospitalization within 2 weeks of study entry. - Transfusion dependency. - Unwilling or unable to give informed consent. - Evidence of any concurrent organ dysfunction listed in Exclusion Co-Existing Conditions. - Unlikely or unable to comply with the requirements of the protocol. Prior Medication: Excluded within 6 weeks of study entry: - Interferons. - Excluded within 45 days of study entry: - Immunosuppressive agents. - Chemotherapy. - Steroids. - Immunomodulators. - Isoprinosine. - BCG vaccine. Prior Treatment: Excluded within 2 weeks of study entry: - Hospitalization. Active intravenous (IV) drug abuse.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "keyword": "Interferon Type I", "mesh_term": ["HIV Infections", "Interferons", "Interferon-alpha"], "id": "NCT00002018"}